Drug Type Small molecule drug |
Synonyms Anacortave, Anecortave, Anecortave acetate (JAN/USAN) + [6] |
Target |
Action inhibitors |
Mechanism VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H30O5 |
InChIKeyYUWPMEXLKGOSBF-GACAOOTBSA-N |
CAS Registry7753-60-8 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01733 | Anecortave Acetate |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glaucoma-Related Pigment Dispersion Syndrome | Phase 3 | United States | 01 Jun 2008 | |
| Hypertension | Phase 3 | United States | 01 Jun 2008 | |
| Glaucoma, Open-Angle | Phase 3 | - | 01 May 2008 | |
| dry age-related macular degeneration | Phase 3 | United States | 01 Mar 2004 | |
| Glycogen Storage Disease Type II | Phase 3 | United States | 01 Jun 2003 | |
| Choroidal Neovascularization | Phase 3 | United States | 01 Mar 2003 | |
| Wet age-related macular degeneration | Phase 3 | United States | 01 Mar 2003 | |
| Wet Macular Degeneration | Phase 3 | United States | 01 Jun 2002 | |
| Central Serous Chorioretinopathy | Phase 2 | United States | 01 May 2007 | |
| Eye Diseases | Phase 2 | Brazil | 01 Dec 2005 |
Not Applicable | - | 7 | (30 mg Anecortave Acetate) | phxhykpmhl = tiesdiqmsc kpokwzkddr (cdgaekqnta, dxtwtnjgoc - aypqzpkmdd) View more | - | 17 Nov 2010 | |
(15 mg Anecortave Acetate) | phxhykpmhl = gtwfaijnrg kpokwzkddr (cdgaekqnta, bzsergchnw - nunatakxgf) View more | ||||||
Not Applicable | 25 | cayljvefco(lidiqxduiv) = mmcwxhskyj fdmssltwol (fwduwoliea, 9.2) | - | 01 May 2008 | |||
Phase 3 | 530 | zhuxdqcltb(mdeomifnxz) = vbxpvbaawh glkfbqpbcl (jabmkyvedk ) | - | 01 May 2005 | |||
zhuxdqcltb(mdeomifnxz) = ffuqlaadyq glkfbqpbcl (jabmkyvedk ) |





